[Hemodynamics and metabolic-energetic expenses of the influence of AR-L115 in patients with coronary artery disease (author's transl)].
AR-L115 has been shown to substantially improve myocardial pump function in patients (pts) with advanced congestive cardiomyopathy by i.v. and by p.o.-route. Since AR-L115 effects on myocardial oxygen consumption (MVO2) and coronary blood flow (CSF) are unknown, the hemodynamic myocardial metabolic and ECG-responses to AR-L115 (2 mg/kg BW bolus) were monitored at the 9, 14 and 19-min interval in 7 patients coronary 3-vessel disease, exhibiting ischemia during pacing stress only. Maximal responses occurred at the 14th min after AR-L115. THere were (average) increases in cardiac index by 30%, in heart rate by 19%, in CSF by 39%, in MVO2 by 34%, and in dp/dt max by 27%. There were (average) decreases in peak systolic pressure by 13%, in PCW by 30%, in LVEDP by 42%, in systemic vascular resistance by 34%, and in coronary vascular resistance by 37%. All changes were significant (p less than 0.05). Unchanged (p greater than 0.05) remained myocardial lactate extraction, stroke work index, and stroke-index. The only moderate increase in MVO2 is possibly explained in that the increase in contractility was a least partially offset by the reductions in pre- and after load. The AR-L115-induced improved pump function was accompanied by moderate increases in MVO2 and CSF, but without evidence of myocardial ischemia.